J. Michael Guenther

University of Tennessee Health Science Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index2.2kcitations37works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(15), Cutaneous Melanoma Detection and Management(8), Nonmelanoma Skin Cancer Studies(7), Breast Lesions and Carcinomas(6), Breast Implant and Reconstruction(6)

Publications37 total

A Prospective, Multicenter Analysis of Recurrence‐Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31‐<scp>GEP</scp>
Cancer Medicine·2025· 2 citedOpen Access
The i31-SLNB Identifies Patients with Cutaneous Melanoma Who Have Less than 5% Risk of SLN Positivity while the CP-GEP does not
SKIN The Journal of Cutaneous Medicine·2025Open Access
Induced mesenchymal stem cells generated from periodontal ligament fibroblast for regenerative therapy
Experimental Biology and Medicine·2025· 3 citedOpen Access
A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma
World Journal of Surgical Oncology·2025· 3 citedOpen Access
Patients who forego sentinel lymph node biopsy after 31-GEP testing are not harmed: A prospective, multicenter analysis
EJC Skin Cancer·2024· 1 citedOpen Access
Clinical use of the 31-gene expression profile for informing sentinel lymph node biopsies: a prospective, multicenter study
SKIN The Journal of Cutaneous Medicine·2023Open Access
The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study
Current Medical Research and Opinion·2023· 10 citedOpen Access
RE: More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population‐based study of 7148 patients
Journal of Surgical Oncology·2022
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction
JCO Precision Oncology·2021· 51 citedOpen Access
Bridging the Gap: Integrating Gene Expression Profiling into Clinical Practice.
PubMed·2021· 11 cited
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Journal of Clinical Oncology·2020· 44 cited
Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance)
Cancer Research·2018· 7 cited
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Journal of Clinical Oncology·2017· 404 citedOpen Access
Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ
Annals of Surgical Oncology·2016· 31 citedOpen Access
Abstract P5-17-03: The 12-gene DCIS score assay: Impact on radiation treatment (XRT) recommendations and clinical utility
Cancer Research·2016· 3 cited
The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12‐gene DCIS score™ result
Journal of Surgical Oncology·2015· 46 cited
Clinical Utility of the 12-Gene Ductal Carcinoma In Situ (DCIS) Score Assay: Impact on Treatment (tx) Recommendations
International Journal of Radiation Oncology*Biology*Physics·2014
Novel Candidate Markers Characterizing Cellular Senescence in Aged Zero Hour Kidney Biopsies Predict Post Transplant Outcome.
Transplantation·2014
Clinical utility of the 12-gene DCIS score assay: Impact on treatment (Tx) recommendations.
Journal of Clinical Oncology·2014
It Is Safe to Perform Gynecologic Surgery First in Patients Undergoing Combined Breast and Gynecologic Surgery
Obstetrics and Gynecology·2014
page 1 of 2Next →

Frequent Co-authors

Matthew J. Ellis(5), Gary Unzeitig(5), Vera J. Suman(4), Jeremy Hoog(4), Kelly K. Hunt(4), Mark A. Watson(4), Andrew Ward(4), Brian J. Martin(4), Charles E. Leonard(4), Jennifer B. Manders(4), Jingqin Luo(3), Katherine DeSchryver(3), D. Craig Allred(3), Laura J. Esserman(3), Gildy V. Babiera(3), Marilyn Leitch(3), John A. Olson(3), David M. Ota(3), Michael Alvarado(3), James E. Hagans(3)